The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial
David W Johnson, Fiona G Brown, Margaret Clarke, Neil Boudville, Tony J Elias, Marjorie WY Foo, Bernard Jones, Hemant Kulkarni, Robyn Langham, Dwarakanathan Ranganathan, John Schollum, Michael G Suranyi, Seng H Tan, David Voss
Nephrology, Dialysis, Transplantation | OXFORD UNIV PRESS | Published : 2012
The balANZ trial was funded by Fresenius Medical Care.David Johnson is a consultant for Baxter Healthcare Pty Ltd and has previously received research funds from this company. He has also received speakers' honoraria and research grants from Fresenius Medical Care. He has previously been a consultant to Gambro Pty Ltd. He is an International Society of Peritoneal Dialysis Councillor and is a current recipient of a Queensland Government Health Research Fellowship. Fiona Brown is a consultant for Baxter and Fresenius. Margaret Clarke is an employee of Fresenius Medical Care. Neil Boudville has previously received research funds from Roche, travel grants from Roche, Amgen and Janssen-Cilag, and speaking honoraria from Roche. Michael Suranyi has participated in company sponsored research for both Baxter and Fresenius. In the past, but not currently, Michael Suranyi has been a member of the Clinical Advisory Boards of Baxter and Fresenius, and has attended sponsored meetings and received honoraria.